Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

Urology group

首页> 外文期刊>Urology >Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

【24h】

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

机译：多西紫杉醇联合雌莫司汀能否延长男性转移性激素难治性前列腺癌的生存期？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Mitoxantrone (Novantrone; OSI, Melville, NY) plus corticosteroids for metastatic androgen-independent prostate cancer relieves pain, but does not prolong survival. Phase l/ll studies have indicated that survival is improved by the combination of docetaxel (Taxotere?; Aventis, Strasbourg, France) and estramustine (Emcyt?; Pfizer, New York, NY).

机译：米托蒽醌（Novantrone; OSI，梅尔维尔，纽约）与皮质类固醇激素可用于转移性雄激素非依赖性前列腺癌，可减轻疼痛，但不能延长生存期。 Ⅰ/Ⅱ期研究表明，多西他赛（Taxotere？; Aventis，法国斯特拉斯堡，法国）和雌莫司汀（Emcyt？; Pfizer，纽约，纽约）的组合可改善生存率。

著录项

来源
《Urology》 |2005年第1期|共2页
作者
Urology group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
androgen-independent; docetaxel; estramustine; prostate cancer; survival;

机译：雄激素非依赖性;多西他赛;雌铁;前列腺癌;生存;

相似文献

外文文献
中文文献
专利

1. Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer? [J] . Urology group Urology . 2005,第1期

机译：多西紫杉醇联合雌莫司汀能否延长男性转移性激素难治性前列腺癌的生存期？
2. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. [J] . Eymard JC, Priou F, Zannetti A, Annals of oncology: official journal of the European Society for Medical Oncology . 2007,第6期

机译：多西他赛联合雌莫司汀和单药多西他赛在转移性激素难治性前列腺癌患者中的随机II期研究。
3. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer [J] . J-C Eymard1 F Priou2 A Zannetti3 A Ravaud4 D Lepillé5 P Kerbrat6 P Gomez7 B Paule8 D Genet9 P Hérait10 E Ecstein-Fraïssé11 and F Joly12 Annals of Oncology . 2007,第6期

机译：多西紫杉醇联合雌莫司汀和单药多西紫杉醇在转移性激素难治性前列腺癌患者中的II期随机研究
4. Thermosensitive Liposomes of Epirubicin combined with hyperthermia enhance brain delivery of epirubicin and prolong survival of mice with metastatic tumors [C] . Yang Yuan, Gong Wei, Lou Kun, Annual meeting exposition of the Controlled Release Society . 2011

机译：表柔比星的热敏脂质体与热疗相结合可增强表柔比星的脑传递并延长转移性肿瘤小鼠的生存期
5. The Impact of Heterogeneity of Treatment Effect on Survival, Cost Effectiveness, and Coverage of Androgen Deprivation Therapy in Metastatic Prostate Cancer [D] . Aly, Abdalla 2015

机译：异质性对转移性前列腺癌生存率，成本效益和雄激素剥夺疗法覆盖率的影响
6. Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study [O] . J Carles, A Font, B Mellado, 2007

机译：多西紫杉醇联合雌莫司汀和塞来昔布在晚期激素难治性前列腺癌患者中的每周给药：II期研究的最终结果
7. Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis [O] . Noah M. Hahn, Sharon Marsh, William Fisher, 2006

机译：Hoosier肿瘤学群随机化II期II研究Docetaxel，Vinorelbine和Estramustine在激素 - 难治性前列腺癌中组合进行药物发生存活分析

Can docetaxel plus estramustine prolong the survival of men with metastatic hormone-refractory prostate cancer?

摘要

著录项

相似文献

相关主题

期刊订阅